Beamtree

ASX Announcement

Beamtree Holdings Limited (ASX:BMT) Sydney, 2 September 2021

Cleansing notice under section 708A of the Corporations Act

As announced by **Beamtree Holdings Limited** (**ASX: BMT**) (formerly PKS Holdings Limited, "**Beamtree**" or the "**Company**") on 1 September 2021, the Company has issued 3,200,000 fully paid ordinary shares as set out in the Appendix 2A (Shares).

The Company gives this notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act), the Company notifies ASX that:

- a) the shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- b) this notice is being given under section 708A(5)(e) of the Corporations Act;
- c) as at the date of this notice, the Company has complied with:
 - i. the provisions of chapter 2M of the Corporations Act as they apply to the Company; and
 - ii. ii. section 674 of the Corporations Act; and
- d) as at the date of this notice, there is no excluded information for the purposes of sections 708A(7) and 708A(8) of the Corporations Act.

Authorised for the release by the Chairman of the Board.

For further information please contact:

Tim Kelsey CEO Beamtree t.kelsey@pks.com.au Mike Hill Chair Beamtree mhill@bomboragroup.com.au

Beamtree

About Beamtree

Beamtree (formerly PKS Holdings) is an Australian pioneer that works with health organisations around the world to better capture, manage and leverage human expertise. At Beamtree we make it simple for healthcare providers to access quality information, automate wherever possible and make informed decisions. Our products enable healthcare organisations to use data and insights in a continuous cycle of learning and improvement, driving quality, safety and efficiency:

- Automated clinical record coding and classification services that are the Australian standard for improving the quality of clinical data and now used internationally to support clinical outcomes and financial efficiency;
- Real time data analytic and benchmarking applications which have proven impact on reducing adverse clinical events and support best value health care;
- Al clinical decision support which automates clinical expertise to minimise data errors and provide real analysis and interpretation in more than 150 locations around the world.